Connection

JULIE BOOM to Respiratory Syncytial Virus Infections

This is a "connection" page, showing publications JULIE BOOM has written about Respiratory Syncytial Virus Infections.
  1. Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children. JAMA Pediatr. 2026 Mar 01; 180(3):314-324.
    View in: PubMed
    Score: 0.182
  2. Hospitalization Outcomes of Full-Term and Premature Children Aged Less Than 2?Years Hospitalized With RSV. Pediatrics. 2026 Feb 01; 157(2).
    View in: PubMed
    Score: 0.181
  3. Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024. JAMA Netw Open. 2025 Sep 02; 8(9):e2531499.
    View in: PubMed
    Score: 0.176
  4. Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis. Pediatrics. 2025 Sep 01; 156(3).
    View in: PubMed
    Score: 0.176
  5. Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 May 08; 74(16):273-281.
    View in: PubMed
    Score: 0.172
  6. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
    View in: PubMed
    Score: 0.169
  7. Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016-2022. Pediatrics. 2024 Jul 01; 154(1).
    View in: PubMed
    Score: 0.162
  8. Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5?Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019. J Pediatr. 2024 08; 271:114045.
    View in: PubMed
    Score: 0.159
  9. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
    View in: PubMed
    Score: 0.159
  10. Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020. Pediatrics. 2024 Mar 01; 153(3).
    View in: PubMed
    Score: 0.158
  11. Factors Associated With Severe Illness in Patients Aged <21 Years Hospitalized for COVID-19. Hosp Pediatr. 2022 09 01; 12(9):760-783.
    View in: PubMed
    Score: 0.143
  12. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020 07; 146(1).
    View in: PubMed
    Score: 0.122
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.